Clinical Trial Update: ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination [Phase 4]

View source ↗

Summary

Phase 4 trial in type 2 diabetes evaluated ADIponectin and ADMA levels after 12 weeks of fixed-dose glimepiride/metformin therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• metformin (metformin)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED